Given children's unique physiological and pharmacokinetic characteristics, the development of pediatric antibiotic formulations requires stringent controls.
Currently, the main clinical treatment methods for refractory Mycoplasma pneumoniae pneumonia (RMPP) after diagnosis include bronchoscope lavage, antibiotic therapy, glucocorticoid therapy, immune modulation treatment, antithrombotic therapy, and integrat